The levels of (accumulated) pesticides detected within honeybee comb wax.

Dissertação de mestrado em Biologia Celular e Molecular, apresentada ao Departamento de Ciências da Vida da Faculdade de Ciências e Tecnologia da Universidade de Coimbra.A doença de Alzheimer (DA) é uma doença neurodegenerativa associada ao envelhecimento e caracterizada por uma deterioração progressiva da memória e de outras funções cognitivas. As características neuropatológicas desta doença incluem perda sináptica e neuronal, acumulação extracelular de péptidos beta-amilóide (Aβ), nas placas amilóides, e agregação de tau hiperfosforilada formando emaranhados neurofibrilares intracelulares. Vários estudos sugerem que na DA a neurogénese no hipocampo está alterada, contribuindo para os défices cognitivos ligados à neurodegenerescência que ocorre nesta doença. A neurogénese adulta é um processo através do qual as células estaminais neurais (CENs) têm capacidade de gerar novos neurónios no cérebro mamífero pós-natal. A neurogénese ocorre em microambientes especializados chamados nichos neurogénicos, onde a vasculatura desempenha um papel importante no funcionamento das CENs. De acordo com descobertas recentes, na DA existe uma associação entre disfunção cerebrovascular, défice cognitivo e neurodegenerescência. Resultados anteriores do nosso grupo de investigação demonstram uma diminuição na neurogénese no giro dentado (GD) do hipocampo de ratinhos machos triplo transgénicos para a DA (3xTg-AD) com 3 meses de idade. A nossa hipótese de trabalho considera que a disfunção vascular precoce na DA pode contribuir para a deterioração observada na neurogénese. Para investigar esta hipótese caracterizamos a vasculatura no GD de ratinhos 3xTg-AD com 3 meses de idade e analisámos a relação entre os vasos sanguíneos e as CENs. Os nossos resultados mostram um decréscimo no volume e na complexidade da vasculatura, dada pela redução no número de ramificações e junções ao longo dos vasos sanguíneos. Além disso, observámos a perda de funcionalidade e integridade dos vasos sanguíneos no GD. Finalmente, um aumento na proximidade de CENS aos vasos sanguíneos foi observado na camada molecular (CM) do GD. Todos os resultados obtidos suportam a ocorrência de alterações precoces na vasculatura do GD de ratinhos 3xTg-AD e a existência de uma estreita relação entre as CENs e os vasos sanguíneos na DA. Os dados apoiam um possível papel dos vasos sanguíneos na redução da neurogénese observada no modelo de ratinho da DA usado. Estes resultados podem assim trazer novas perspetivas no que diz respeito ao envolvimento das alterações cerebrovasculares na redução da neurogénese que é observada na DA.Alzheimer’s disease (AD) is an age-related neurodegenerative disease characterized by a progressive deterioration of memory and other cognitive functions. The neuropathological hallmarks of this disorder include synaptic and neuronal loss, extracellular accumulation of amyloid-beta (Aβ) peptide in amyloid plaques and aggregation of hyperphosphorylated tau forming intracellular neurofibrillary tangles. Several findings suggest that impaired hippocampal neurogenesis may contribute to AD-related cognitive deficits linked to neurodegeneration. Adult neurogenesis is a process through which neural stem cells (NSCs) have the capacity to generate new neurons in the post-natal mammalian brain. Adult neurogenesis occurs within specialized microenvironments called neurogenic niches where vasculature plays an important role in NSCs fate. According to recent findings, there is an association between cerebrovascular dysfunction, cognitive deficit and neurodegeneration in AD. Previous results from our lab support a decrease in the neurogenesis occurring in the hippocampal dentate gyrus (DG) of 3 month-old triple transgenic (3xTg-AD) male mice. Therefore, we hypothesize that early AD-related vascular dysfunction may account for the observed impairment in neurogenesis. To explore this, we further characterize the vasculature in the DG of 3 month-old 3xTg-AD mice and analyze the relationship between blood vessels and NSCs. Our results show a decrease in the volume and complexity of the vasculature, given by a reduction in the number of branches and junctions per length of blood vessels. In addition, loss of functionality and integrity of blood vessels was also observed in this region. Furthermore, an increase in the proximity of stem cells processes to blood vessels was found in the molecular layer (ML) of DG. Taken together, these results support the occurrence of early alterations in the vasculature of the DG of 3xTg-AD mice and a close relationship between NSCs and blood vessels, which may play a role in reduced neurogenesis observed in this AD mouse model. These findings may bring new perspectives in the involvement of cerebrovascular changes in the neurogenesis impairment that occurs in AD

The Eleventh and Twelfth Data Releases of the Sloan Digital Sky Survey: Final Data from SDSS-III

The third generation of the Sloan Digital Sky Survey (SDSS-III) took data from 2008 to 2014 using the original SDSS wide-field imager, the original and an upgraded multi-object fiber-fed optical spectrograph, a new near-infrared high-resolution spectrograph, and a novel optical interferometer. All of the data from SDSS-III are now made public. In particular, this paper describes Data Release 11 (DR11) including all data acquired through 2013 July, and Data Release 12 (DR12) adding data acquired through 2014 July (including all data included in previous data releases), marking the end of SDSS-III observing. Relative to our previous public release (DR10), DR12 adds one million new spectra of galaxies and quasars from the Baryon Oscillation Spectroscopic Survey (BOSS) over an additional 3000 deg2 of sky, more than triples the number of H-band spectra of stars as part of the Apache Point Observatory (APO) Galactic Evolution Experiment (APOGEE), and includes repeated accurate radial velocity measurements of 5500 stars from the Multi-object APO Radial Velocity Exoplanet Large-area Survey (MARVELS). The APOGEE outputs now include the measured abundances of 15 different elements for each star. In total, SDSS-III added 5200 deg2 of ugriz imaging; 155,520 spectra of 138,099 stars as part of the Sloan Exploration of Galactic Understanding and Evolution 2 (SEGUE-2) survey; 2,497,484 BOSS spectra of 1,372,737 galaxies, 294,512 quasars, and 247,216 stars over 9376 deg2; 618,080 APOGEE spectra of 156,593 stars; and 197,040 MARVELS spectra of 5513 stars. Since its first light in 1998, SDSS has imaged over 1/3 of the Celestial sphere in five bands and obtained over five million astronomical spectra. \ua9 2015. The American Astronomical Society

SDSS-III: Massive Spectroscopic Surveys of the Distant Universe, the Milky Way Galaxy, and Extra-Solar Planetary Systems

Building on the legacy of the Sloan Digital Sky Survey (SDSS-I and II), SDSS-III is a program of four spectroscopic surveys on three scientific themes: dark energy and cosmological parameters, the history and structure of the Milky Way, and the population of giant planets around other stars. In keeping with SDSS tradition, SDSS-III will provide regular public releases of all its data, beginning with SDSS DR8 (which occurred in Jan 2011). This paper presents an overview of the four SDSS-III surveys. BOSS will measure redshifts of 1.5 million massive galaxies and Lya forest spectra of 150,000 quasars, using the BAO feature of large scale structure to obtain percent-level determinations of the distance scale and Hubble expansion rate at z<0.7 and at z~2.5. SEGUE-2, which is now completed, measured medium-resolution (R=1800) optical spectra of 118,000 stars in a variety of target categories, probing chemical evolution, stellar kinematics and substructure, and the mass profile of the dark matter halo from the solar neighborhood to distances of 100 kpc. APOGEE will obtain high-resolution (R~30,000), high signal-to-noise (S/N>100 per resolution element), H-band (1.51-1.70 micron) spectra of 10^5 evolved, late-type stars, measuring separate abundances for ~15 elements per star and creating the first high-precision spectroscopic survey of all Galactic stellar populations (bulge, bar, disks, halo) with a uniform set of stellar tracers and spectral diagnostics. MARVELS will monitor radial velocities of more than 8000 FGK stars with the sensitivity and cadence (10-40 m/s, ~24 visits per star) needed to detect giant planets with periods up to two years, providing an unprecedented data set for understanding the formation and dynamical evolution of giant planet systems. (Abridged)Comment: Revised to version published in The Astronomical Journa

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review

Background Rupture of the spleen in the absence of trauma or previously diagnosed disease is largely ignored in the emergency literature and is often not documented as such in journals from other fields. We have conducted a systematic review of the literature to highlight the surprisingly frequent occurrence of this phenomenon and to document the diversity of diseases that can present in this fashion. Methods Systematic review of English and French language publications catalogued in Pubmed, Embase and CINAHL between 1950 and 2011. Results We found 613 cases of splenic rupture meeting the criteria above, 327 of which occurred as the presenting complaint of an underlying disease and 112 of which occurred following a medical procedure. Rupture appeared to occur spontaneously in histologically normal (but not necessarily normal size) spleens in 35 cases and after minor trauma in 23 cases. Medications were implicated in 47 cases, a splenic or adjacent anatomical abnormality in 31 cases and pregnancy or its complications in 38 cases. The most common associated diseases were infectious (n = 143), haematologic (n = 84) and non-haematologic neoplasms (n = 48). Amyloidosis (n = 24), internal trauma such as cough or vomiting (n = 17) and rheumatologic diseases (n = 10) are less frequently reported. Colonoscopy (n = 87) was the procedure reported most frequently as a cause of rupture. The anatomic abnormalities associated with rupture include splenic cysts (n = 6), infarction (n = 6) and hamartomata (n = 5). Medications associated with rupture include anticoagulants (n = 21), thrombolytics (n = 13) and recombinant G-CSF (n = 10). Other causes or associations reported very infrequently include other endoscopy, pulmonary, cardiac or abdominal surgery, hysterectomy, peliosis, empyema, remote pancreato-renal transplant, thrombosed splenic vein, hemangiomata, pancreatic pseudocysts, splenic artery aneurysm, cholesterol embolism, splenic granuloma, congenital diaphragmatic hernia, rib exostosis, pancreatitis, Gaucher's disease, Wilson's disease, pheochromocytoma, afibrinogenemia and ruptured ectopic pregnancy. Conclusions Emergency physicians should be attuned to the fact that rupture of the spleen can occur in the absence of major trauma or previously diagnosed splenic disease. The occurrence of such a rupture is likely to be the manifesting complaint of an underlying disease. Furthermore, colonoscopy should be more widely documented as a cause of splenic rupture

The tenth data release of the Sloan Digital Sky Survey:first spectroscopic data from the SDSS-III Apache Point Observatory Galactic Evolution Experiment

The Sloan Digital Sky Survey (SDSS) has been in operation since 2000 April. This paper presents the Tenth Public Data Release (DR10) from its current incarnation, SDSS-III. This data release includes the first spectroscopic data from the Apache Point Observatory Galaxy Evolution Experiment (APOGEE), along with spectroscopic data from the Baryon Oscillation Spectroscopic Survey (BOSS) taken through 2012 July. The APOGEE instrument is a near-infrared R ~ 22,500 300 fiber spectrograph covering 1.514–1.696 μm. The APOGEE survey is studying the chemical abundances and radial velocities of roughly 100,000 red giant star candidates in the bulge, bar, disk, and halo of the Milky Way. DR10 includes 178,397 spectra of 57,454 stars, each typically observed three or more times, from APOGEE. Derived quantities from these spectra (radial velocities, effective temperatures, surface gravities, and metallicities) are also included. DR10 also roughly doubles the number of BOSS spectra over those included in the Ninth Data Release. DR10 includes a total of 1,507,954 BOSS spectra comprising 927,844 galaxy spectra, 182,009 quasar spectra, and 159,327 stellar spectra selected over 6373.2 deg2.</p

The Tenth Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the SDSS-III Apache Point Observatory Galactic Evolution Experiment

The Sloan Digital Sky Survey (SDSS) has been in operation since 2000 April. This paper presents the Tenth Public Data Release (DR10) from its current incarnation, SDSS-III. This data release includes the first spectroscopic data from the Apache Point Observatory Galaxy Evolution Experiment (APOGEE), along with spectroscopic data from the Baryon Oscillation Spectroscopic Survey (BOSS) taken through 2012 July. The APOGEE instrument is a near-infrared R similar to 22,500 300 fiber spectrograph covering 1.514-1.696 mu m. The APOGEE survey is studying the chemical abundances and radial velocities of roughly 100,000 red giant star candidates in the bulge, bar, disk, and halo of the Milky Way. DR10 includes 178,397 spectra of 57,454 stars, each typically observed three or more times, from APOGEE. Derived quantities from these spectra (radial velocities, effective temperatures, surface gravities, and metallicities) are also included. DR10 also roughly doubles the number of BOSS spectra over those included in the Ninth Data Release. DR10 includes a total of 1,507,954 BOSS spectra comprising 927,844 galaxy spectra, 182,009 quasar spectra, and 159,327 stellar spectra selected over 6373.2 deg(-2)